Department of Obstetrics and Gynecology, The Second Affiliated Hospital of Anhui Medical University, No 678 Furong Road, Hefei, 230022, Anhui, China.
Department of Obstetrics and Gynecology, The Frist Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
Sci Rep. 2024 May 30;14(1):12447. doi: 10.1038/s41598-024-63457-2.
The innate immune molecule NLR family CARD domain-containing 5 (NLRC5) plays a significant role in endometrial carcinoma (EC) immunosurveillance. However, NLRC5 also plays a protumor role in EC cells. Mismatch repair gene deficiency (dMMR) can enable tumors to grow faster and also can exhibit high sensitivity to immune checkpoint inhibitors. In this study, we attempted to determine whether NLRC5-mediated protumor role in EC is via the regulation of dMMR. Our findings revealed that NLRC5 promoted the proliferation, migration, and invasion abilities of EC cells and induced the dMMR status of EC in vivo and in vitro. Furthermore, the mechanism underlying NLRC5 regulated dMMR was also verified. We first found NLRC5 could suppress nuclear factor-kappaB (NF-κB) pathway in EC cells. Then we validated that the positive effect of NLRC5 in dMMR was restricted when NF-κB was activated by lipopolysaccharides in NLRC5-overexpression EC cell lines. In conclusion, our present study confirmed the novel NLRC5/NF-κB/MMR regulatory mechanism of the protumor effect of NLRC5 on EC cells, thereby suggesting that the NLRC5-mediated protumor in EC was depend on the function of MMR.
天然免疫分子 NLR 家族 CARD 结构域包含 5(NLRC5)在子宫内膜癌(EC)免疫监视中发挥重要作用。然而,NLRC5 在 EC 细胞中也发挥促肿瘤作用。错配修复基因缺陷(dMMR)可使肿瘤生长更快,并对免疫检查点抑制剂表现出高度敏感性。在这项研究中,我们试图确定 NLRC5 是否通过调节 dMMR 介导 EC 的促肿瘤作用。我们的研究结果表明,NLRC5 促进了 EC 细胞的增殖、迁移和侵袭能力,并在体内和体外诱导了 EC 的 dMMR 状态。此外,还验证了 NLRC5 调节 dMMR 的机制。我们首先发现 NLRC5 可以抑制 EC 细胞中的核因子-κB(NF-κB)通路。然后我们验证了当 NLRC5 过表达的 EC 细胞系中 NF-κB 被脂多糖激活时,NLRC5 在 dMMR 中的正效应受到限制。总之,本研究证实了 NLRC5/NF-κB/MMR 调节机制在 NLRC5 对 EC 细胞促肿瘤作用中的新作用,从而提示 NLRC5 介导的 EC 促肿瘤作用依赖于 MMR 的功能。
World J Gastroenterol. 2019-6-28
Cancers (Basel). 2025-4-25
Cell Commun Signal. 2025-1-23
Biochim Biophys Acta Mol Cell Biol Lipids. 2023-5
Technol Cancer Res Treat. 2022